Human heterochromatin protein 1 Isoforms regulate androgen receptor signaling in prostate cancer

Journal of Molecular Endocrinology

Volumn 50, Issue 3, 2013, Pages 401-409

  Itsumi, Momoe ^a   Shiota, Masaki ^a   Yokomizo, Akira ^a   Kashiwagi, Eiji ^a   Takeuchi, Ario ^a   Tatsugami, Katsunori ^a   Inokuchi, Junichi ^a   Song, Yoohyun ^a   Uchiumi, Takeshi ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Androgen receptor; Castration resistant prostate cancer; Heterochromatin protein 1; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; HETEROCHROMATIN PROTEIN 1; HETEROCHROMATIN PROTEIN 1 ALPHA; HETEROCHROMATIN PROTEIN 1 BETA; HETEROCHROMATIN PROTEIN 1 GAMMA; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING;

EID: 84876710388     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-13-0024     Document Type: Article

References (43)

1. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ et al. 2012 Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. Journal of the National Cancer Institute 104 125-132. (doi:10.1093/jnci/djr500)
2. Ayoub N, Jeyasekharan AD & Venkitaraman AR 2009 Mobilization and recruitment of HP1: a bimodal response to DNA breakage. Cell Cycle 8 2945-2950.
3. Baxter J, Sauer S, Peters A, John R, Williams R, Caparros ML, Arney K, Otte A, Jenuwein T, Merkenschlager M et al. 2004 Histone hypomethylation is an indicator of epigenetic plasticity in quiescent lymphocytes. EMBO Journal 23 4462-4472. (doi:10.1038/sj.emboj.7600414)
4. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY et al. 2010 H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Research 70 7830-7840. (doi:10.1158/0008-5472.CAN-10-0833)
5. Cryderman DE, Tang H, Bell C, Gilmour DS & Wallrath LL 1999 Heterochromatic silencing of Drosophila heat shock genes acts at the level of promoter potentiation. Nucleic Acids Research 27 3364-3370. (doi:10.1093/nar/27.16.3364)
6. De Koning L, Savignoni A, Boumendil C, Rehman H, Asselain B, Sastre-Garau X & Almouzni G 2009 Heterochromatin protein 1a: a hallmark of cell proliferation relevant to clinical oncology. EMBO Molecular Medicine 1 178-191. (doi:10.1002/emmm.200900022)
7. Dialynas GK, Terjung S, Brown JP, Aucott RL, Baron-Luhr B, Singh PB & Georgatos SD 2007 Plasticity of HP1 proteins in mammalian cells. Journal of Cell Science 120 3415-3424. (doi:10.1242/jcs.012914)
8. Dialynas GK, Vitalini MW & Wallrath LL 2008 Linking heterochromatin protein 1 (HP1) to cancer progression. Mutation Research 647 13-20. (doi:10.1016/j.mrfmmm.2008.09.007)
9. Dinant C & Luijsterburg MS 2009 The emerging role of HP1 in the DNA damage response. Molecular and Cellular Biology 29 6335-6340. (doi:10.1128/MCB.01048-09)
10. Fanti L & Pimpinelli S 2008 HP1: a functionally multifaceted protein. Current Opinion in Genetics & Development 18 169-174. (doi:10.1016/j.gde.2008.01.009)
11. Gilbert N, Boyle S, Sutherland H, de Las Heras J, Allan J, Jenuwein T & Bickmore WA 2003 Formation of facultative heterochromatin in the absence of HP1. Insulation of the chicken beta-globin chromosomal domain from a chromatin-condensing protein, MENT. EMBO Journal 22 5540-5550. (doi:10.1093/emboj/cdg520)
12. Hediger F & Gasser SM 2006 Heterochromatin protein 1, don't judge the book by its cover!. Current Opinion in Genetics & Development 16 143-150. (doi:10.1016/j.gde.2006.02.013)
13. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E & Lilja H 2010 Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncology 11 725-732. (doi:10.1016/S1470-2045(10)70146-7)
14. Kim J, Lee JH & Iyer VR 2008 Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS ONE 3 e1798. (doi:10.1371/journal.pone.0001798)
15. Kirschmann DA, Seftor EA, Nieva DR, Mariano EA & Hendrix MJ 1999 Differentially expressed genes associated with the metastatic phenotype in breast cancer. Breast Cancer Research and Treatment 55 127-136. (doi:10.1023/A:1006188129423)
16. Kirschmann DA, Lininger RA, Gardner LM, Seftor EA, Odero VA, Ainsztein AM, Earnshaw WC, Wallrath LL & Hendrix MJ 2000 Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer. Cancer Research 60 3359-3363.
17. Kwon SH & Workman JL 2011 The changing faces of HP1: from heterochromatin formation and gene silencing to euchromatic gene expression: HP1 acts as a positive regulator of transcription. BioEssays 33 280-289. (doi:10.1002/bies.201000138)
18. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ & Ren B 2003 A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. PNAS 100 8164-8169. (doi:10.1073/pnas.1332764100)
19. Nielsen AL, Ortiz JA, You J, Oulad-Abdelghani M, Khechumian R, Gansmuller A, Chambon P & Losson R 1999 Interaction with members of the heterochromatin protein 1 (HP1) family and histone deacetylation are differentially involved in transcriptional silencing by members of the TIF1 family. EMBO Journal 18 6385-6395. (doi:10.1093/emboj/18.22.6385)
20. Norwood LE, Moss TJ, Margaryan NV, Cook SL, Wright L, Seftor EA, Hendrix MJ, Kirschmann DA & Wallrath LL 2006 A requirement for dimerization of HP1Hsalpha in suppression of breast cancer invasion. Journal of Biological Chemistry 281 18668-18676. (doi:10.1074/jbc.M512454200)
21. Oberley MJ, Inman DR & Farnham PJ 2003 E2F6 negatively regulates BRCA1 in human cancer cells without methylation of histone H3 on lysine 9. Journal of Biological Chemistry 278 42466-42476. (doi:10.1074/jbc.M307733200)
22. Piacentini L, Fanti L, Berloco M, Perrini B & Pimpinelli S 2003 Heterochromatin protein 1 (HP1) is associated with induced gene expression in Drosophila euchromatin. Journal of Cell Biology 161 707-714. (doi:10.1083/jcb.200303012)
23. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C et al. 2002 Prediction of central nervous systemembryonal tumour outcome based on gene expression. Nature 415 436-442. (doi:10.1038/415436a)
24. Ritou E, Bai M & Georgatos SD 2007 Variant-specific patterns and humoral regulation of HP1 proteins in human cells and tissues. Journal of Cell Science 120 3425-3435. (doi:10.1242/jcs.012955)
25. Ruginis T, Taglia L, Matusiak D, Lee BS & Benya RV 2006 Consequence of gastrin-releasing peptide receptor activation in a human colon cancer cell line: a proteomic approach. Journal of Proteome Research 5 1460-1468. (doi:10.1021/pr060005g)
26. Ryan CJ & Tindall DJ 2011 Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. Journal of Clinical Oncology 29 3651-3658. (doi:10.1200/JCO.2011.35.2005)
27. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M et al. 2009 Screening and prostate-cancer mortality in a randomized European study. New England Journal of Medicine 360 1320-1328. (doi:10.1056/NEJMoa0810084)
28. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M et al. 2012 Prostate-cancer mortality at 11 years of follow-up. New England Journal of Medicine 366 981-990. (doi:10.1056/NEJMoa1113135)
29. Shapiro E, Huang H, Ruoff R, Lee P, Tanese N & Logan SK 2008 The heterochromatin protein 1 family is regulated in prostate development and cancer. Journal of Urology 179 2435-2439. (doi:10.1016/j.juro.2008. 01.091)
30. Sharma GG, Hwang KK, Pandita RK, Gupta A, Dhar S, Parenteau J, Agarwal M, Worman HJ, Wellinger RJ & Pandita TK 2003 Human heterochromatin protein 1 isoforms HP1(Hsa) and HP1(Hsb) interfere with hTERT-telomere interactions and correlate with changes in cell growth and response to ionizing radiation. Molecular and Cellular Biology 23 8363-8376. (doi:10.1128/MCB.23.22.8363-8376.2003)
31. Shigemura K, Sung SY, Kubo H, Arnold RS, Fujisawa M, Gotoh A, Zhau HE & Chung LW 2007 Reactive oxygen species mediate androgen receptorand serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate 67 722-731. (doi:10.1002/pros.20565)
32. Shiota M, Song Y, Yokomizo A, Tada Y, Kuroiwa K, Eto M, Oda Y, Inokuchi J, Uchiumi T, Fujimoto N et al. 2010a Human heterochromatin protein 1 isoform HP1b enhances androgen receptor activity and is implicated in prostate cancer growth. Endocrine-Related Cancer 17 455-467. (doi:10.1677/ERC-09-0321)
33. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T & Naito S 2010b Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 29 237-250. (doi:10.1038/onc.2009.322)
34. Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, Kuroiwa K, Tatsugami K, Fujimoto N, Oda Y et al. 2011a Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. Endocrine-Related Cancer 18 505-517. (doi:10.1530/ERC-11-0017)
35. Shiota M, Yokomizo A, Kashiwagi E, Takeuchi A, Fujimoto N, Uchiumi T & Naito S 2011b Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. Free Radical Biology & Medicine 51 78-87. (doi:10.1016/j.freeradbiomed.2011.04.001)
36. Siegel R, Naishadham D & Jemal A 2012 Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62 10-29. (doi:10.3322/caac.20138)
37. Takanashi M, Oikawa K, Fujita K, Kudo M, Kinoshita M & Kuroda M 2009 Heterochromatin protein 1g epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers. American Journal of Pathology 174 309-316. (doi:10.2353/ajpath.2009.080148)
38. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K & Joensuu H 2003 Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clinical Cancer Research 9 68-75.
39. Weinmann AS, Yan PS, Oberley MJ, Huang TH & Farnham PJ 2002 Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes and Development 16 235-244. (doi:10.1101/gad.943102)
40. de Wit E, Greil F & van Steensel B 2007 High-resolution mapping reveals links of HP1 with active and inactive chromatin components. PLoS Genetics 3 e38. (doi:10.1371/journal.pgen.0030038)
41. Zarebski M, Wiernasz E & Dobrucki JW 2009 Recruitment of heterochromatin protein 1 to DNA repair sites. Cytometry. Part A 75 619-625. (doi:10.1002/cyto.a.20734)
42. Zhang R & Adams PD 2007 Heterochroma tin and its relationship to cellsenescence and cancer therapy. Cell Cycle 6 784-789. (doi:10.4161/cc.6.7.4079)
43. Zhao T, Heyduk T, Allis CD & Eissenberg JC 2000 Heterochromatin protein 1 binds to nucleosomes and DNA in vitro. Journal of Biological Chemistry 275 28332-28338. (doi:10.1074/jbc.M003493200)